What is claimed is:

1. A compound of formula (I)



(I)

wherein

Ar^1 is selected from benzodioxolyl, pyrrolidinyl,

pyridyl or pyridyl N-oxide, each optionally mono-substituted with $C(O)NH_2$, halo, $(C_1\text{-}C_3)$alkoxy, amino, hydroxy$(C_1\text{-}C_3)$alkyl, or $(C_1\text{-}C_3)$alkyl optionally substituted with aminocarbonyl or $(C_1\text{-}C_3)$alkylcarbonylamino,

a five-membered aromatic heterocycle optionally substituted with 1 or 2 substituents each independently selected from $(C_1\text{-}C_3)$alkyl, C(O)H, $C(O)(C_1\text{-}C_3)$alkyl, and halo, and

phenyl optionally substituted with 1 or 2 substituents each selected independently from OH, $-OCF_3$, CF_3, CN, halo, NO_2, NR^5R^5, $NHC(O)R^6$, $NHS(O)_2R^5$, $NHS(O)_2NR^5R^5$, $S(O)_nR^8$, $C(O)R^{10}$, $C(O)NH(C_1\text{-}C_3)$alkoxy-$(C_1\text{-}C_3)$alkyl, $C(O)NH(C_3\text{-}C_6)$cycloalkyl, pyrrolidinonyl, imidazolinyl, imidazolidinonyl, $(C_1\text{-}C_3)$alkoxy optionally substituted with 1 or 2 OH groups, and

$(C_1\text{-}C_3)$alkyl optionally mono-substituted with CN, OH, NR^5R^5, $NHC(O)R^6$, $NHS(O)_2(C_1\text{-}C_3)$alkyl, $C(O)NR^5R^5$, oxazolidinonyl, imidazolidinonyl optionally mono-substituted with $(C_1\text{-}C_3)$alkyl, pyrrolidinonyl optionally mono-substituted with $(C_1\text{-}C_3)$alkyl, a five-membered N containing heterocycle optionally mono-substituted with $(C_1\text{-}C_3)$alkyl, piperazinyl optionally mono-substituted with $(C_1\text{-}C_3)$alkyl, pyridyl optionally mono-substituted with CF_3, or $(C_1\text{-}C_3)$alkoxy, thienyl optionally mono-substituted with $C(O)(C_1\text{-}C_3)$alkyl, or pyrimidinyl optionally mono-substituted with $N[(C_1\text{-}C_3)alkyl]_2$;

Ar^2 is selected from benzodioxolyl,

phenyl optionally substituted with 1 or 2 substituents each selected independently from $(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, OH, NO_2, CN, halo, and CF_3, and

pyridyl mono-substituted with $(C_1\text{-}C_3)$alkyl, or CF_3;

R^1 is selected from H, $(C_1\text{-}C_3)$alkyl, OH, and halo;

R^2 is selected from H, $(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, OH, halo, CF_3, and $-OCF_3$;

R^3 is selected from H, $(C_1\text{-}C_3)$alkoxy, OH, halo, and CF_3;

R^4 is selected from hydrogen, $(C_1\text{-}C_3)$alkyl, $(C_1\text{-}C_3)$alkoxy, CN, and $C(O)NHR^5$, wherein $(C_1\text{-}C_3)$alkyl can optionally be substituted with halo, $(C_1\text{-}C_3)$alkoxy, hydroxyalkylamino, alkoxyalkylamino;

R^5 is selected from H, $(C_3\text{-}C_6)$cycloalkyl, and

$(C_1\text{-}C_3)$alkyl optionally substituted with 1 or 2 OH groups or

mono-substituted with $(C_1\text{-}C_3)$alkoxy, $(C_1\text{-}C_3)$alkylamino, $S(O)_2(C_1\text{-}C_3)$alkyl, or $C(O)R^7$;

R^6 is selected from H, $(C_3\text{-}C_6)$cycloalkyl, $(C_1\text{-}C_3)$alkoxy, $(C_2\text{-}C_6)$alkenyl, CHF_2, CF_3, NHR^5, and $(C_1\text{-}C_3)$alkyl optionally substituted with one or more substituents selected from Cl and F, or optionally mono-substituted with NH_2 or $NHC(O)(C_1\text{-}C_3)$alkyl;

R^7 is selected from $(C_1\text{-}C_3)$alkoxy, $(C_2\text{-}C_6)$alkenyl, CHF_2, CF_3, $(C_3\text{-}C_6)$cycloalkyl, $NR^{7\text{-}1}R^{7\text{-}1}$, and $(C_1\text{-}C_3)$alkyl optionally substituted with one or more substituents selected from Cl and F, or mono-substituted with $NHC(O)(C_1\text{-}C_3)$alkyl or NH_2, wherein $R^{7\text{-}1}$ is hydrogen or $(C_1\text{-}C_3)$alkyl;

R^8 is selected from $(C_1\text{-}C_3)$alkyl and NR^9R^9;

R^9 is selected from H, and $(C_1\text{-}C_3)$alkyl optionally mono-substituted with $(C_1\text{-}C_3)$alkoxy, or aminocarbonyl, or substituted with 1 or 2 OH groups;

R^{10} is selected from H, $(C_1\text{-}C_3)$alkoxy, NHR^9, and

$(C_1\text{-}C_3)$alkyl optionally mono-substituted with pyrrolidinyl, morpholinyl, pyridinyl, piperazinyl optionally substituted with $(C_1\text{-}C_3)$alkyl, or piperidinyl optionally substituted with $(C_1\text{-}C_3)$alkyl;

n is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein Ar^1 is

phenyl optionally substituted with 1 or 2 substituents each selected independently from OH, $-OCF_3$, CF_3, CN, halo, NO_2, NR^5R^5, $NHC(O)R^6$, $NHS(O)_2R^5$, $NHS(O)_2NR^5R^5$, $S(O)_nR^8$, $C(O)R^{10}$, $C(O)NH(C_1\text{-}C_3)$alkoxy-$(C_1\text{-}C_3)$alkyl, $C(O)NH(C_3\text{-}C_6)$cycloalkyl, pyrrolidinonyl, imidazolinyl, imidazolidinonyl, $(C_1\text{-}C_3)$alkoxy optionally substituted with 1 or 2 OH groups, and

$(C_1\text{-}C_3)$alkyl optionally mono-substituted with CN, OH, NR^5R^5, $NHC(O)R^6$, $NHS(O)_2(C_1\text{-}C_3)$alkyl, $C(O)NR^5R^5$, oxazolidinonyl,

imidazolidinonyl optionally mono-substituted with $(C_1$-$C_3)$alkyl,
pyrrolidinonyl optionally mono-substituted with $(C_1$-$C_3)$alkyl,
a five-membered N containing heterocycle optionally
mono-substituted with $(C_1$-$C_3)$alkyl,
piperazinyl optionally mono-substituted with $(C_1$-$C_3)$alkyl,
pyridyl optionally mono-substituted with CF_3, or $(C_1$-$C_3)$alkoxy,
thienyl optionally mono-substituted with $C(O)(C_1$-$C_3)$alkyl, or
pyrimidinyl optionally mono-substituted with $N[(C_1$-$C_3)alkyl]_2$,

R^5 is selected from H, $(C_3$-$C_6)$cycloalkyl, and
$(C_1$-$C_3)$alkyl optionally substituted with 1 or 2 OH groups or
mono-substituted with $(C_1$-$C_3)$alkoxy, $(C_1$-$C_3)$alkylamino, $S(O)_2(C_1$-$C_3)$alkyl, or $C(O)R^7$;

R^6 is selected from H, $(C_3$-$C_6)$cycloalkyl, $(C_1$-$C_3)$alkoxy, $(C_2$-$C_6)$alkenyl, CHF_2, CF_3, NHR^5, and $(C_1$-$C_3)$alkyl optionally substituted with one or more substituents selected from Cl and F, or optionally mono-substituted with NH_2 or $NHC(O)(C_1$-$C_3)$alkyl;

R^7 is selected from $(C_1$-$C_3)$alkoxy, $(C_2$-$C_6)$alkenyl, CHF_2, CF_3, $(C_3$-$C_6)$cycloalkyl, $NR^{7\text{-}1}R^{7\text{-}1}$, and $(C_1$-$C_3)$alkyl optionally substituted with one or more substituents selected from Cl and F, or mono-substituted with $NHC(O)(C_1$-$C_3)$alkyl or NH_2,
wherein $R^{7\text{-}1}$ is hydrogen, methyl or ethyl;

R^8 is selected from $(C_1$-$C_3)$alkyl and NR^9R^9;

R^9 is selected from H, and $(C_1$-$C_3)$alkyl optionally mono-substituted with $(C_1$-$C_3)$alkoxy, or aminocarbonyl, or substituted with 1 or 2 OH groups;

R^{10} is selected from H, $(C_1$-$C_3)$alkoxy, NHR^9, and
$(C_1$-$C_3)$alkyl optionally mono-substituted with pyrrolidinyl, morpholinyl, pyridinyl, piperazinyl optionally substituted with $(C_1$-$C_3)$alkyl, or piperidinyl optionally substituted with $(C_1$-$C_3)$alkyl;

3. The compound of claim 1, wherein Ar^2 is 2,4-dihalosubstituted phenyl.

4. The compound of claim 1, wherein Ar^2 is 2,4-dichlorophenyl.

5. The compound of claim 1, wherein R^1, R^2 and R^3 are hydrogen.

6. A process for preparing a compound of Claim 1, wherein a compound of formula (X)



(X)

wherein R^1 to R^4 and Ar^2 have the meaning indicated in claim 1,

is reacted with a compound (IV)

Ar^1-$B(OR')_2$ (IV),

wherein Ar^1 has the meaning indicated in claim 1, and where R' is selected in each instance independently from H and (C_1-C_3)alkyl, or (IV) represents



(IVa)

or



(IVb),

in the presence of a palladium catalyst and base.

7. The compound of claim 1 for the treatment and/or prophylaxis of disorders.

8. A pharmaceutical composition comprising a compound according to claim 1.

9. A pharmaceutical composition comprising a compound according to claim 1 in combination with at least one pharmaceutically acceptable excipient.

10. A process for preparing the pharmaceutical composition of claim 9, comprising combining at least one compound of claim 1 with at least one pharmaceutically acceptable excipient, mixing the combination and bringing the combination into a suitable administration form.

11. The pharmaceutical composition of claim 8 for the treatment or prophylaxis of hyperproliferative disorders.

12. The use of a compound according to claim 1 for manufacturing a medicament for the treatment or prophylaxis of hyperproliferative disorders.

13. A method of treating a disease or condition in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound according to the formula (I).

14. The method of claim 13, wherein the disease or condition is a hyperproliferative disorder.